Related Experiment Video
Updated: Jun 10, 2026
07:30
Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
Published on: May 10, 2018
PROTAC-Mediated DPP-4 Degradation: A New Solution for Type 2 Diabetes.
1Institute of Functional Nano & Soft Materials (FUNSOM), Biomedical Basic Research Center (BBRC) of Jiangsu Province, Engineering Research Center of RNA Medicine and Cell Therapy Technology, Ministry of Education, Soochow University, 199 Ren'ai Road, Suzhou, 215123 Jiangsu, PR China.
Journal of Medicinal Chemistry
|June 8, 2026
Summary
Dipeptidyl peptidase-4 (DPP-4) inhibition is key for type 2 diabetes. Proteolysis-targeting chimera (PROTAC) technology offers a novel approach for sustained glycemic control by degrading DPP-4.
Area of Science:
- Biochemistry
- Endocrinology
- Pharmacology
Background:
- Dipeptidyl peptidase-4 (DPP-4) exacerbates type 2 diabetes mellitus (T2DM) by degrading glucagon-like peptide-1 (GLP-1).
- Current DPP-4 inhibitors offer only moderate therapeutic benefits due to insufficient sustained inhibition.
- Targeted protein degradation presents a promising strategy for enhanced T2DM management.
Purpose of the Study:
- To explore proteolysis-targeting chimera (PROTAC) technology for sustained DPP-4 inhibition.
- To investigate PROTACs as a novel therapeutic strategy for type 2 diabetes mellitus.
Main Methods:
- Utilizing proteolysis-targeting chimera (PROTAC) technology.
- Developing novel PROTACs to target DPP-4 for degradation.
Main Results:
- PROTAC-mediated targeted degradation of DPP-4 offers a potential for sustained glycemic control.
- This approach may overcome the limitations of current small-molecule DPP-4 inhibitors.
Conclusions:
- Targeted degradation of DPP-4 via PROTAC technology is a viable alternative strategy for T2DM treatment.
- PROTACs hold promise for achieving sustained glycemic control in patients with type 2 diabetes mellitus.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...